Company intelligence / Profile preview
Endolipid Therapeutics
Barcelona, Catalonia, Spainendolipid.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has conducted in vitro and in vivo experiments with positive results and plans to continue studies in animal models before advancing to human trials. They expect their technology to reach the market for treating non-alcoholic fatty liver disease within five years from 2021.
- Therapeutic areas
- GastroenterologyDermatology
- Modalities
- Peptides (SHBG-mimic peptides)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
VHIR (Vall d'Hebron Institut de Recerca)Genesis Ventures
Beyond the preview
Go deeper on Endolipid Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endolipid Therapeutics.